ASCO 2023 | How can results for the AURORA sub-analysis influence future studies?

Elisa Agostinetto, MD, Institut Jules Bordet, Brussels, Belgium, states the exploratory nature of the AURORA (NCT02102165) sub-analysis and its intention for hypothesis formation. The data collected is key in understanding the heterogeneity in relation to CDK4/6 inhibitors. Furthermore, identifying characteristics linked with a worse prognosis may aid in the formation of clinical trials, where alternative therapies to CDK4/6 inhibitors could be studied. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.